2017;73:61–70. 28. Kwok D, Okada H. T-Cell based therapies for overcoming neuroanatomical and immunosup - pressive challenges within the glioma microenvi- ronment. J Neurooncol. 2020;147(2):281–295. 29. Nejo T, Yamamichi A, Almeida ND, Goretsky YE, Okada H. Tumor antigens in glioma. Semin Immunol. 2020;47:101385. 30. Alban TJ, et al. Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. JCI Insight . 2018;3(21):122264. 31. Weiss T, Vitacolonna M, Zöller M. The effica - cy of an IL-1alpha vaccine depends on IL-1RI availability and concomitant myeloid-derived suppressor cell reduction. J Immunother. 2009;32(6):552–564. 32.